BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at up to $67.4 million for the advanced development of a smallpox biodefense therapeutic.
{iframe}https://globalbiodefense.com/2021/02/19/biofactura-funded-13m-contract-option-for-smallpox-biodefense-therapeutic/{/iframe}